



Product Data Sheet

Product Name: OVA (257-264)
Catalog Number: AS-60193-1 (1 mg) Lot Number: See label on vial
AS-60193-5 (5 mg)
Sequence: H-Ser-Ile-Ile-Asn-Phe-Glu-Lys-Leu-OH (3-letter code)
SIINFEKL (1-letter code)
Molecular Weight: 963.2
% Peak Area by HPLC: ≥95

Appearance: Lyophilized white powder

Peptide Reconstitution: Use distilled or higher quality water. Add water directly to the lyophilized peptide powder to obtain a final concentration of approximately 0.5 mg/mL to 1mg/mL or less. Gently vortex to mix. For peptides that have poor solubility in the suggested solvent, brief sonication may increase solubility in some cases.

Storage: Peptide is shipped at ambient temperature. Upon receipt, store lyophilized powder at –20°C or lower. Reconstituted peptide should be aliquoted into several freezer vials and stored at –20°C or lower. Do not freeze thaw.

Description: This is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb. Ref: Werlen, G. et al. *Nature* **406**, 422 (2000); Maecker, H. et al. *J Immunol* **161**, 6532 (1998).

Additional Information: Listed below are relevant information that may provide a guideline on how to use this product. End users will have to adapt to their own specific applications.

Ovalbumin (OVA257–264) peptide–SIINFEKL (single letter amino acid designation) and BCR/ABL fusion junction peptide–GFKQSSKAL (GFK), both from Anaspec, Inc. (San Jose, CA, USA), were reconstituted in water - [Kislin, K. L. et al. *FASEB J* **21**, 2173 \(2007\).](#)

One marrow cells of WT and IL-15R α –/– mice were cultured *ex vivo* for 5–6 days, then stimulated with 5 ng/ml LPS and 1 μ g/ml OVA peptide (257–264; SIINFEKL; AnaSpec, San Jose, CA) overnight. WT DCs were injected (0.33 million s.c. plus 0.66 million i.p.) into WT mice, and IL-15R α –/–DCs were injected into IL-15R α –/– mice - [Sato, N. et al. *Proc Natl Acad Sci* **104**, 588 \(2007\).](#)

EL4 cells or EL4-Necl2 stable transfectants were incubated for 2 h with 100 μ M H2-K(b)-restricted OVA-derived peptide (SIINFEKL, Anaspec Inc., San Jose, CA), washed extensively, and cocultured with CD8+ T purified from the spleen and lymph nodes of two female OT1 mice using a Miltenyi Biotech CD8+ T-cell-negative enrichment kit according to the manufacturer's specifications- [Galibert, L. et al. *J Biol Chem* **280**, 21955 \(2005\).](#)

Published Citations:

[Faisal, S. et al. *Vaccine* doi:10.1016/j.vaccine.2011.01.110 \(2011\).](#)
[Durgan, K. et al. *Cancer Immunol Immunotherapy* 10.1007/s00262-010-0963-5 \(2010\).](#)
[Fletcher, A. et al. *JEM* **207**, 689 \(2010\).](#)
[Kelly, R. et al. *Blood* **115**, 1088 \(2010\).](#)
[Sun X. et al. *J Control Release* 10.1016/j.jconrel.2010.06.017 \(2010\).](#)
[Ordaz, M. et al. *Cell Immunol* **262**, 141 \(2010\).](#)
[Bowers, V. et al. *J Leukoc Biol* **10**, 1189 \(2009\).](#)

[Nakayama, M. et al. *Blood* **113**, 3821 \(2009\).](#)
[Peng, YF. et al. *J Immunol* **182**, 2777 \(2009\).](#)
[Qu, C. et al. *J Immunol* **182**, 3650 \(2009\).](#)
[Kelly, R. et al. *Blood* **111**, 5734 \(2008\).](#)
[Towne, C.F. et al. *J Immunol* **180**, 1704 \(2008\).](#)
[Kislin, K. L. et al. *FASEB J* **21**, 2173 \(2007\).](#)
[Sato, N. et al. *Proc Natl Acad Sci* **104**, 588 \(2007\).](#)
[Canté-Barrett, K. et al. *J Immunol* **176**, 2299 \(2006\).](#)
[Ren, Y. et al. *Graefe's Arch Clin Exp Ophthalmol* **244**, 1315 \(2006\).](#)
[Galibert, L. et al. *J Biol Chem* **280**, 21955 \(2005\).](#)
[Komlosh, A. et al. *J Biol Chem* **276**, 30050 \(2001\).](#)
[Ben-Shahar, S. et al. *J Biol Chem* **274**, 21963 \(1999\).](#)
[Ben-Shahar, S. et al. *J Biol Chem* **272**, 21060 \(1997\).](#)

For Research Use Only